The Multiple Sclerosis Drug Development Landscape
Multiple Sclerosis continues to be a key area of drug development innovation, owing to its complex pathology, diverse symptom profile, and unmet therapeutic needs, offering substantial potential for novel therapeutic interventions.
The report offers insight into:
- Clinical Trial Initiations: 59 trials are set to conclude in 2025, reflecting sustained momentum in therapeutic development
- Biomarkers: Neurofilament light chain is the most frequently studied, enabling earlier intervention and personalized treatment strategies
- Drug Targets: CD20 and BTK the most disclosed, highlighting the focus on B cell-driven pathology
- Therapeutic Classes: Cell Therapies the most investigated class, with Antibodies a close second
You May Also Be Interested In…
Learn More About Autoimmune
What is Beacon Autoimmune?
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
